Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

Hypomethylating agent (HMA) failure in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) carries a poor prognosis with limited treatment options. Although intensive, remission induction chemotherapy is often used subsequently, in particular to bridge to allogeneic transplantation, it...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Blood Adv
मुख्य लेखकों: Ball, Brian, Komrokji, Rami S., Adès, Lionel, Sekeres, Mikkael A., DeZern, Amy E., Pleyer, Lisa, Vey, Norbert, Almeida, Antonio, Germing, Ulrich, Cluzeau, Thomas, Platzbecker, Uwe, Gore, Steven D., Fenaux, Pierre, Prebet, Thomas
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Hematology 2018
विषय:
Clinical Trials and Observations
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6113613/
https://ncbi.nlm.nih.gov/pubmed/30120104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018015529
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन